WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PTGX

Based on 10 analysts offering 12 month price targets for Protagonist Therapeutics Inc

Min Forecast
$73.00-10.9%
Avg Forecast
$99.20+21.08%
Max Forecast
$118.00+44.03%

Should I buy or sell PTGX stock?

Based on 10 analysts offering ratings for Protagonist Therapeutics Inc.

Strong Buy
Strong Buy
6 analysts 60%
Buy
4 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PTGX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PTGX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PTGX stock forecasts and price targets.

PTGX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-02
lockedlocked$00.00+00.00%2026-01-30
lockedlocked$00.00+00.00%2026-01-05Find Out Why
lockedlocked$00.00+00.00%2025-12-17Find Out Why
lockedlocked$00.00+00.00%2025-12-08Find Out Why
JP Morgan
Top 28%
73
Strong BuyMaintains$81.00-1.14%2025-11-07
Citizens
Top 3%
98
BuyMaintains$102.00+24.50%2025-11-07
Wedbush
Bottom 5%
5
BuyMaintains$86.00+4.97%2025-10-28
BTIG
Top 4%
97
Strong BuyReiterates$82.00+0.09%2025-10-28
Leerink Partners
Top 17%
84
BuyInitiates Coverage On$73.00-10.90%2025-09-12

1 of 1

Forecast return on equity

Is PTGX forecast to generate an efficient return?

Company
30.4%
Industry
275.71%
Market
238.37%
PTGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PTGX forecast to generate an efficient return on assets?

Company
27.96%
Industry
114.68%
PTGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PTGX earnings per share forecast

What is PTGX's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$0.37-51.55%
Avg 2 year Forecast
-$1.33-272.87%
Avg 3 year Forecast
$1.25+62.05%

PTGX revenue forecast

What is PTGX's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$291.5M+39.32%
Avg 2 year Forecast
$141.0M-32.6%
Avg 3 year Forecast
$278.6M+33.17%
PTGX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PTGX revenue growth forecast

How is PTGX forecast to perform vs Biotechnology companies and vs the US market?

Company
-1.03%
Industry
119.45%
Market
23.3%
PTGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PTGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PTGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PTGX$81.93$99.20+21.08%Strong Buy
IMVT$25.64$35.33+37.80%Buy
COGT$36.72$40.50+10.29%Buy
MIRM$102.01$108.33+6.20%Strong Buy
CELC$104.87$105.86+0.94%Strong Buy
View Top Biotech Stocks

Protagonist Therapeutics Stock Forecast FAQ

Is Protagonist Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 10 Wall Street analysts covering (NASDAQ: PTGX) stock is to Strong Buy PTGX stock.

Out of 10 analysts, 6 (60%) are recommending PTGX as a Strong Buy, 4 (40%) are recommending PTGX as a Buy, 0 (0%) are recommending PTGX as a Hold, 0 (0%) are recommending PTGX as a Sell, and 0 (0%) are recommending PTGX as a Strong Sell.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

What is PTGX's earnings growth forecast for 2026-2028?

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.

Protagonist Therapeutics's earnings in 2026 is $45,909,000.On average, 15 Wall Street analysts forecast PTGX's earnings for 2026 to be $23,324,595, with the lowest PTGX earnings forecast at -$144,586,232, and the highest PTGX earnings forecast at $330,832,904. On average, 12 Wall Street analysts forecast PTGX's earnings for 2027 to be -$83,214,603, with the lowest PTGX earnings forecast at -$130,495,201, and the highest PTGX earnings forecast at $6,564,145.

In 2028, PTGX is forecast to generate $78,007,048 in earnings, with the lowest earnings forecast at -$21,442,873 and the highest earnings forecast at $191,673,032.

What is PTGX's revenue growth forecast for 2026-2028?

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of -1.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 119.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.3%.

Protagonist Therapeutics's revenue in 2026 is $209,217,000.On average, 15 Wall Street analysts forecast PTGX's revenue for 2026 to be $18,222,066,326, with the lowest PTGX revenue forecast at $1,225,307,054, and the highest PTGX revenue forecast at $34,461,760,883. On average, 12 Wall Street analysts forecast PTGX's revenue for 2027 to be $8,815,334,063, with the lowest PTGX revenue forecast at $2,442,424,555, and the highest PTGX revenue forecast at $17,651,923,452.

In 2028, PTGX is forecast to generate $17,418,114,861 in revenue, with the lowest revenue forecast at $7,903,230,496 and the highest revenue forecast at $27,857,605,926.

What is PTGX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PTGX) forecast ROA is 27.96%, which is lower than the forecast US Biotechnology industry average of 114.68%.

What is PTGX's Price Target?

According to 10 Wall Street analysts that have issued a 1 year PTGX price target, the average PTGX price target is $99.20, with the highest PTGX stock price forecast at $118.00 and the lowest PTGX stock price forecast at $73.00.

On average, Wall Street analysts predict that Protagonist Therapeutics's share price could reach $99.20 by Feb 2, 2027. The average Protagonist Therapeutics stock price prediction forecasts a potential upside of 21.08% from the current PTGX share price of $81.93.

What is PTGX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PTGX) Protagonist Therapeutics's current Earnings Per Share (EPS) is $0.77. On average, analysts forecast that PTGX's EPS will be $0.37 for 2026, with the lowest EPS forecast at -$2.31, and the highest EPS forecast at $5.29. On average, analysts forecast that PTGX's EPS will be -$1.33 for 2027, with the lowest EPS forecast at -$2.09, and the highest EPS forecast at $0.11. In 2028, PTGX's EPS is forecast to hit $1.25 (min: -$0.34, max: $3.07).

What is PTGX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PTGX) forecast ROE is 30.4%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.